ROS clearance, mitochondrial protection, and CaMKII/CREB pathway activation are promising treatments for glaucoma.[36, 37, 38, 39] In this study, we developed hypoxia and ROS dual response nano drugs (HOLN‐NPs), which can release Nico and OA under hypoxic environments and ROS conditions. Here, CAMK2G is linked to glaucoma.